Exponent (NASDAQ:EXPO) Downgraded by Zacks Investment Research

Zacks Investment Research lowered shares of Exponent (NASDAQ:EXPO) from a buy rating to a hold rating in a research report released on Tuesday, Zacks.com reports.

According to Zacks, “Exponent, Inc., is a multidisciplinary organization of scientists, physicians, engineers and business consultants performing in-depth scientific research and analysis in over 90 technical disciplines. The company is an engineering and scientific consulting firm providing solutions to complex problems. The firm has been best known for analyzing accidents and failures to determine their causes, but in recent years it has become more active in assisting clients with human health, environmental and engineering issues associated with new products to help prevent problems in the future. The Company serves clients in the automotive, aviation, chemical, construction, consumer products, energy, government, health, insurance, manufacturing, technology and other sectors. “

Several other equities analysts have also issued reports on the company. BidaskClub lowered Vertex Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, July 9th. Cantor Fitzgerald restated a buy rating on shares of Tivity Health in a research note on Monday, April 22nd. Finally, William Blair restated a market perform rating on shares of W W Grainger in a research note on Monday, April 22nd. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $65.33.

Shares of Exponent stock traded up $5.09 during trading on Tuesday, reaching $66.63. The company’s stock had a trading volume of 4,004 shares, compared to its average volume of 177,093. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.22 and a current ratio of 4.22. The stock has a fifty day moving average price of $58.44. The company has a market cap of $3.16 billion, a price-to-earnings ratio of 53.26 and a beta of 0.44. Exponent has a one year low of $44.44 and a one year high of $61.71.

Exponent (NASDAQ:EXPO) last posted its quarterly earnings data on Thursday, July 18th. The business services provider reported $0.39 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.06. The business had revenue of $106.50 million for the quarter, compared to analyst estimates of $95.77 million. Exponent had a return on equity of 23.10% and a net margin of 19.53%. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.34 earnings per share. On average, equities research analysts anticipate that Exponent will post 1.42 EPS for the current fiscal year.

In related news, Director Carol Lindstrom sold 1,800 shares of the business’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $56.92, for a total transaction of $102,456.00. Following the transaction, the director now directly owns 3,212 shares in the company, valued at $182,827.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.30% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EXPO. Norges Bank acquired a new stake in Exponent during the fourth quarter valued at approximately $27,435,000. FMR LLC boosted its holdings in Exponent by 39.8% during the first quarter. FMR LLC now owns 993,288 shares of the business services provider’s stock valued at $57,333,000 after purchasing an additional 282,530 shares in the last quarter. Ellis Investment Partners LLC acquired a new stake in Exponent during the first quarter valued at approximately $90,000. Isthmus Partners LLC boosted its holdings in Exponent by 208.5% during the first quarter. Isthmus Partners LLC now owns 96,172 shares of the business services provider’s stock valued at $7,771,000 after purchasing an additional 64,995 shares in the last quarter. Finally, First Trust Advisors LP boosted its holdings in Exponent by 109.9% during the first quarter. First Trust Advisors LP now owns 112,759 shares of the business services provider’s stock valued at $6,508,000 after purchasing an additional 59,029 shares in the last quarter. 88.68% of the stock is currently owned by institutional investors.

Exponent Company Profile

Exponent, Inc, together with its subsidiaries, operates as a science and engineering consulting company worldwide. Its services include analysis of product development, product recall, regulatory compliance, and the discovery of potential problems related to products, people, property, and impending litigation.

Recommended Story: Cost of equity and a company’s balance sheet

Get a free copy of the Zacks research report on Exponent (EXPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Exponent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exponent and related companies with MarketBeat.com's FREE daily email newsletter.